SecBot SecBot
Insider Cluster (2 insiders) ·Filed Jul 6, 2026

SRRK

Scholar Rock Holding Corp
NEUTRAL
Impact 2/10
Horizonimmediate Processed3mo ago
Insider cluster: 2 insiders, $124K total
Actionable Insight • Neutral

This cluster carries no actionable signal. Monitor for any change in C-suite insider activity or an SEC filing (e.g., earnings, pipeline update) that might explain a shift in director behavior, but $124K in director sales at a $6.6B biotech is routine portfolio adjustment.

DirectionNeutral
Confidencehigh
Horizonimmediate
Final — all horizons settled through T+60d
SRRK ▼ -14.57% at T+60d
NEUTRAL call -14.57% · α vs SPY -16.56% · entry $56.56 → $48.32
Entry = T+0 close
Jul 6, 2026
via day close
T+1d
-0.94%
call -0.94% · α -0.63%
$56.03
settled 4mo ago
T+5d
-4.92%
call -4.92% · α -5.47%
$53.78
settled 4mo ago
T+20d
-15.51%
call -15.51% · α -18.66%
$47.79
settled 3mo ago
T+60d
-14.57%
call -14.57% · α -16.56%
$48.32
settled 27d ago

Price Chart

Loading chart...

Executive Summary

Two directors at Scholar Rock sold a combined ~$124K in open-market transactions on July 1, 2026, representing ~0.002% of the company's $6.6B market cap. This is a trivial insider cluster — both the absolute dollar amount and proportionality to market cap are negligible. Per Alldredge (2019), cluster sales are not more informative than non-cluster sales, and directors carry weaker signal than C-suite executives.

Key Financial Metrics

Direction
selling
Total Value
$124.0K
Insiders
2

Key Facts

  • Total insider sales: ~$124K (0.002% of $6.6B market cap)
  • Two selling insiders: Directors Kristina Burow and Michael Gilman
  • All sales were open-market transactions on July 1, 2026
  • No C-suite officers (CEO/CFO/CSO) participated in the cluster
  • Recent 30-day insider activity: 5 prior sells totaling $301K

Financial Impact

Total sales of ~$124K, or 0.002% of market capitalization. Immaterial.

insider_holdings

Risk Factors

  • Directors sold ahead of any upcoming clinical data readout, though the dollar amount is so small it is unlikely to reflect material negative information.
  • The 96% analyst buy rating creates high expectations — any pipeline setback would be amplified.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
96% bullish (24 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-SRRK-1783408745337
9 reports for SRRK
Performance horizon
75% Hit rate @ T+1 3 of 4 directional calls Went positive at some point 3 of 4 best @ T+5▲ +5.04%Apr 16, 2026
Filters
Rows
Reports for SRRK — sortable, filterable
TypeNow
Sep 15, 2026
5w ago
8-K
NEUTRAL ★ 3/10
$50.00 $49.49▼ −1.03%▼ −1.36%$41.29 (−17.41%)
Sep 14, 2026
6w ago
8-K
BULLISH ★ 8/10
$51.85 $50.00▼ −3.57%▼ −3.11%$41.29 (−20.36%)
Aug 6, 2026
11w ago
8-K
NEUTRAL ★ 5/10
$52.64 $52.92▲ +0.53%▼ −0.08%$41.29 (−21.55%)
Jul 6, 2026
15w ago
Insider Cluster
NEUTRAL ★ 2/10
$56.56 $56.03▼ −0.94%▼ −0.63%$41.29 (−26.99%)
Jun 11, 2026
19w ago
Institutional Cluster
BEARISH ★ 6/10
$44.69 $44.18▲ +1.14%▲ +1.68%$41.29 (+7.60%)
May 7, 2026
24w ago
8-K
MIXED ★ 6/10
$46.45 $48.39▲ +4.18%▲ +3.35%$41.29 (−11.10%)
Apr 16, 2026
27w ago
Insider Cluster
BEARISH ★ 7/10
$50.00 $49.96▲ +0.08%▲ +1.29%$41.29 (+17.41%)
Apr 16, 2026
27w ago
Insider Cluster
BEARISH ★ 6/10
$50.00 $49.96▲ +0.08%▲ +1.29%$41.29 (+17.41%)
Mar 27, 2026
30w ago
Institutional Cluster
MIXED ★ 6/10
$42.60 $43.08▲ +1.13%▲ +1.48%$41.29 (−3.06%)
Showing 9 of 9

US Market Status

Market Open — Closes in 5h 23m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 7, 2026